Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).

New antibody-drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry - offering seven times better efficacy than existing approaches.

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities. The Kobe University achievement is the result of a rational design strategy that yields a platform for the industrial production of drug candidates.

Plants produce many substances with promising pharmacological activities. For example, Rhododendron species produce a class of compounds, called orsellinic acid-derived meroterpenoids, with remarkable anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.

PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair.

Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer's disease. The team found that removing an enzyme from neurons in the brain substantially reduces amyloid plaques - a hallmark characteristic of the disease - and may provide further resilience against disease progression.

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, often driven by abnormal lipid metabolism and excessive blood vessel growth. In a new study, researchers from Fudan University and Wenzhou Medical University have uncovered how disulfiram - a long-used anti-alcoholism medication - exerts potent anti-tumor effects in liver cancer.

Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, with significant residual risk unexplained by traditional factors. The discovery of novel therapeutic targets or the repurposing of existing drug targets could improve the prevention and treatment for different CVDs. However, previous studies have encountered different analytic challenges, such as failing to cover the whole spectrum of CVDs,

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune cells recognize gradually vanish. Researchers at the Technical University of Munich (TUM) have now identified one of the molecular mechanisms behind this process. In an initial study they succeeded in blocking it using an existing cancer drug.

Patients who use semaglutide for weight loss, like Ozempic, are more likely to continue the medication if they perceive it as effective, even when facing unpleasant side effects, according to Rutgers Health researchers.

Their study, published in Journal of Medical Internet Research, found perceived effectiveness - reductions in weight, appetite or food cravings - was the strongest predictor of satisfaction and intention to continue treatment, regardless of side effects.

Pfizer Inc. (NYSE: PFE) announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. The program provides Americans a wide range of more than 30 medicines at a significant discount off list prices.

Whether a smartphone battery lasts longer or a new drug can be developed to treat incurable diseases depends on how stably the atoms constituting the material are bonded. The core of 'molecular design' lies in finding how to arrange these countless atoms to form the most stable molecule. Until now, this process has been as difficult as finding the lowest valley in a massive mountain range, requiring immense time and costs.

Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL ("bad") cholesterol levels and have been repeatedly proven to reduce the risk of cardiovascular disease. However, there have been concerns about possible side effects.

Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead 7/12/2024

Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition 7/12/2024

AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report 7/12/2024

Akebia Ends Deal With CSL Vifor, Unveils Hefty Price Tag for CKD Anemia Drug Vafseo 7/12/2024

PBMs and Big Pharma Play Blame Game for Inflated Prescription Drug Prices 7/12/2024

Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff 7/12/2024

FDA Decision Tracker: Novo’s Once-Weekly Insulin Icodec Rejected 7/12/2024

EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm 4/12/2024